These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2081790)

  • 1. Current state of the hybridoma technology.
    Pirofski L; Casadevall A; Rodriguez L; Zuckier LS; Scharff MD
    J Clin Immunol; 1990 Nov; 10(6 Suppl):5S-12S; discussion 12S-14S. PubMed ID: 2081790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of monoclonal antibodies to plant pathogens.
    Thornton CR
    Methods Mol Biol; 2009; 508():63-74. PubMed ID: 19301747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production and Screening of Monoclonal Peptide Antibodies.
    Trier NH; Mortensen A; Schiolborg A; Friis T
    Methods Mol Biol; 2015; 1348():109-26. PubMed ID: 26424268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of mice and men: hybridoma and recombinant antibodies.
    Little M; Kipriyanov SM; Le Gall F; Moldenhauer G
    Immunol Today; 2000 Aug; 21(8):364-70. PubMed ID: 10916138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative effect of multiple antigen injections on the yield of murine monoclonal antibodies obtained by hybridoma technology.
    Néron S; Lemieux R
    Hybridoma; 1992 Oct; 11(5):639-44. PubMed ID: 1459586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a strategy for the rapid generation of a monoclonal antibody against the human protein SNEV (hNMP200) by flow-cytometric cell sorting.
    Böhm E; Grillari J; Voglauer R; Gross S; Ernst W; Ferko B; Kunert R; Katinger H; Borth N
    J Immunol Methods; 2005 Dec; 307(1-2):13-23. PubMed ID: 16289093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybridoma technology: the preferred method for monoclonal antibody generation for
    Zaroff S; Tan G
    Biotechniques; 2019 Sep; 67(3):90-92. PubMed ID: 31347924
    [No Abstract]   [Full Text] [Related]  

  • 8. Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique.
    Glukhova XA; Prusakova OV; Trizna JA; Zaripov MM; Afanas'eva GV; Glukhov AS; Poltavtseva RA; Ivanov AA; Avila-Rodriguez M; Barreto GE; Aliev G; Beletsky IP
    Curr Pharm Des; 2016; 22(7):870-8. PubMed ID: 26696411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies.
    Smith SA; Crowe JE
    Microbiol Spectr; 2015 Feb; 3(1):AID-0027-2014. PubMed ID: 26104564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybridoma Technology.
    Hnasko RM; Stanker LH
    Methods Mol Biol; 2015; 1318():15-28. PubMed ID: 26160560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of monoclonal antibodies.
    Yokoyama WM
    Curr Protoc Cytom; 2006 Aug; Appendix 3():Appendix 3J. PubMed ID: 18770829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transgenesis and humanization of murine antibodies].
    Cogné M; Duchez S; Pascal V
    Med Sci (Paris); 2009 Dec; 25(12):1149-54. PubMed ID: 20035696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of a panel of monoclonal antibodies and polyclonal sera against anthrax toxins resulted in identification of an anti-lethal factor antibody with disease-enhancing characteristics.
    Kulshreshtha P; Tiwari A; Priyanka ; Joon S; Sinha S; Bhatnagar R
    Mol Immunol; 2015 Dec; 68(2 Pt A):185-93. PubMed ID: 26364143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybridoma-free generation of monoclonal antibodies.
    Pasqualini R; Arap W
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):257-9. PubMed ID: 14688405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody engineering, a strategy for the development of monoclonal antibodies.
    Schönherr OT; Houwink EH
    Antonie Van Leeuwenhoek; 1984; 50(5-6):597-623. PubMed ID: 6099095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renewal of EBV-hybridoma method: efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells.
    Ainai A; Kawase T; Ida A; Maeda Y; Ohba H; Ikeda Y; Sato H; Takahashi M; Chiba J
    Hum Antibodies; 2006; 15(4):139-54. PubMed ID: 17522436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro B-lymphocyte antigen priming against both non-immunogenic and immunogenic molecules requiring low amounts of antigen and applicable in hybridoma technology.
    Brams P; Pettijohn DE; Brown M; Olsson L
    J Immunol Methods; 1987 Apr; 98(1):11-22. PubMed ID: 2435806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
    Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
    J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies and Selection of Monoclonal Antibodies.
    Hanack K; Messerschmidt K; Listek M
    Adv Exp Med Biol; 2016; 917():11-22. PubMed ID: 27236550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of chimeric monoclonal antibodies from mice that carry human immunoglobulin Cgamma1 heavy of Ckappa light chain gene segments.
    Pluschke G; Joss A; Marfurt J; Daubenberger C; Kashala O; Zwickl M; Stief A; Sansig G; Schläpfer B; Linkert S; van der Putten H; Hardman N; Schröder M
    J Immunol Methods; 1998 Jun; 215(1-2):27-37. PubMed ID: 9744745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.